Back to results
US 8,889,861 B2Granted
Crystalline forms of a purine derivative
AssigneeCyclacel Limited
InventorsBenjamin Mark Skead, Christopher Peter Worrall, Jonathan Charles Christian Atherton, Julian Scott Northen, Philippe Fernades
Life of this patent
Estimating the term…
Abstract
The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
Claims4
A crystalline form of compound (I),
- which is an L-tartrate salt;
- and which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2[theta] values selected from 6.67 ±0.2, 8.237±0.2, 9.777 ±0.2, 11.96 ±0.2, 12.38 ±0.2, 13.06 ±0.2, 13.38 ±0.2, 13.94 ±0.2, 14.90 ±0.2, 15.40 ±0.2, 15.95 ±0.2, 16.27 ±0.2, 16.54 ±0.2, 17.36 ±0.2, 17.57 ±0.2, 17.86 ±0.2, 19.64 ±0.2, 19.86 ±0.2, 20.12 ±0.2, 20.73 ±0.2, 21.14 ±0.2, 21.58 ±0.2, 22.57 ±0.2, 22.95 ±0.2, 23.29 ±0.2, 23.57 ±0.2, 24.07 ±0.2, 24.63 ±0.2, 25.30 ±0.2, 26.38 ±0.2, 27.09 ±0.2, 27.67 ±0.2, 27.97 ±0.2, 28.91 ±0.2, 29.28 ±0.2, 30.08 ±0.2, 30.41 ±0.2, 31.90 ±0.2 and 34.49 ±0.2 (Form E).
A crystalline form of compound (I),
- which is an L-tartrate salt;
- and which is characterized by an x-ray powder diffraction pattern having two or more diffraction peaks at 2[theta] values selected from 3.82 ±0.2, 7.57 ±0.2, 8.12 ±0.2, 10.53 ±0.2, 11.39 ±0.2, 12.00 ±0.2, 13.54 ±0.2, 15.15 ±0.2, 16.35 ±0.2, 16.88 ±0.2, 17.37 ±0.2, 18.51 ±0.2, 18.98 ±0.2, 19.77±0.2, 21.06 ±0.2, 22.70 ±0.2, 23.47 ±0.2, 24.66 ±0.2 and 28.73 ±0.2 [Form D].
Dependencies are inferred from the claim text.